| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02120638 | Multidrug Resistant Tuberculosis | Drug: Pyrazinamide containing regimen|Drug: Regimen without Pyrazinamide | Huashan Hospital | Phase 3 | 2014-04-01 | 2014-04-21 |
| NCT02128308 | Healthy | Drug: Levofloxacin and Streptomycin added|Drug: Moxifloxacin and Kanamycin added | Seoul National University Hospital | Phase 1 | 2013-11-01 | 2014-04-29 |
| NCT02409290 | MDR-TB | Drug: Regimen A locally-used WHO-approved MDR-TB regimen|Drug: Moxifloxacin|Drug: Clofazimine|Drug: Ethambutol|Drug: Pyrazinamide|Drug: Isoniazid|Drug: Prothionamide|Drug: Kanamycin|Drug: Levofloxacin|Drug: Bedaquiline | IUATLD, Inc|Medical Research Council | Phase 3 | 2016-04-01 | 2016-05-31 |
| NCT00513396 | Tuberculosis, Multidrug-Resistant | Drug: Isoniazid|Drug: Placebo | GSVM Medical College | Phase 2|Phase 3 | 2004-01-01 | 2007-08-06 |
| NCT02496572 | Multidrug Resistant Tuberculosis | Drug: Short course MDR-TB treatment regimen | Medecins Sans Frontieres, Netherlands|Ministry of Health, Republic of Uzbekistan|Imperial College London | Phase 3 | 2013-09-01 | 2015-07-09 |
| NCT03057756 | Multi-drug Resistant Tuberculosis | Combination Product: Km+ Mfx+ Pto + H + Cfz +E+Z | Centre de Recherche Mdicale de Lambarn|Institute of Tropical Medicine, University of Tuebingen|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | | 2015-09-11 | 2017-02-17 |
| NCT00042289 | HIV Infections | Drug: atazanavir/cobicistat|Drug: darunavir/ritonavir|Drug: darunavir/cobicistat|Drug: etravirine|Drug: elvitegravir/cobicistat|Drug: dolutegravir|Drug: tenofovir alafenamide fumarate (TAF)|Drug: TAF/cobicistat|Drug: TAF/ritonavir|Drug: efavirenz|Drug: lopinavir/ritonavir|Drug: nevirapine|Drug: rifampicin|Drug: ethambutol|Drug: isoniazid|Drug: pyrazinamide|Drug: rifampicin|Drug: kanamycin|Drug: amikacin|Drug: capreomycin|Drug: moxifloxacin|Drug: levofloxacin|Drug: ofloxacin|Drug: ethionamide/prothionamide|Drug: terizidone/cycloserine|Drug: para-aminosalicylic acid (PAS)|Drug: high dose isoniazid (INH)|Drug: bedaquiline|Drug: clofazamine|Drug: delamanid|Drug: linezolid|Drug: pretomanid|Drug: atazanavir/ritonavir/tenofovir|Drug: ethinyl estradiol oral contraceptive|Drug: etonogestrel implant | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 4 | 2003-03-01 | 2017-03-13 |
